Results 111 to 120 of about 1,781,035 (303)
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
, 1984 The antigenic relationships between the prolamins of barley, rye and wheat have been studied by examining the specificity of an antibody to ‘C’ hordein in a quantitative study using a laser nephelometer.
Miflin, B. J. +3 more
core +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Complement-Mediated Virus Infectivity Neutralisation by HLA Antibodies Is Associated with Sterilising Immunity to SIV Challenge in the Macaque Model for HIV/AIDS. [PDF]
, 2014 Sterilising immunity is a desired outcome for vaccination against human immunodeficiency virus (HIV) and has been observed in the macaque model using inactivated simian immunodeficiency virus (SIV).
Mark Robinson +20 more
core +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
A Western Blot and Immunoprecipitation Assay to Verify Antibody Specificity
BioTechniques, 2015 Life scientists are raising awareness of the problem of irreproducible data in basic research (1) (2). Part of the crisis of irreproducibility has been blamed on antibodies (3), and from this standpoint, an equal push to bring awareness to antibody ...
Sharon Bonnette
doaj +1 more source
Antibody targeted nanoparticles for imaging and therapy of cancer [PDF]
, 2010 The central hypothesis for this thesis is that antibody-targeted superparamagnetic iron oxide nanoparticles (SPIONs) can be used for diagnosis and therapy of cancer.
Vigor, K.L.
core
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
A) Representative immunoblots showing the specificity of the two hERG protein bands (150 and kDa) in SH-SY5Y cells exposed to normoxia (N) or 2days of hypoxia (CH2d) probed with hERG antibody (left two lanes) or with hERG antibody preadsorbed overnight ...
Jayasri Nanduri (467086) +5 more
core +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source